SLU-PP-332 Purity & Testing — Research Reference
SLU-PP-332 stands as a pivotal research compound, functioning as an estrogen-related-receptor (ERR) agonist with significant implications for understanding metabolic regulation and exercise physiology. Rigorous purity assessment and comprehensive testing are paramount to ensure the integrity and reproducibility of experimental outcomes across in vitro and in vivo research models.
The compound’s mechanism of action, targeting ERR pathways, has garnered considerable scientific interest, leading to numerous publications indexed in PubMed and several registered studies on ClinicalTrials.gov, underscoring its relevance in current investigative landscapes. This reference provides an in-depth review of SLU-PP-332’s characteristics, research applications, and the critical quality control measures necessary for its effective use in advanced biological research.
Physicochemical Properties and Structural Characterization of SLU-PP-332
SLU-PP-332, a novel compound identified as an estrogen-related receptor (ERR) agonist, possesses distinct physicochemical properties that are paramount for its utility and performance in research settings. Understanding these attributes is fundamental for accurate dosing, appropriate formulation development in preclinical models, and ensuring the stability and integrity of the compound throughout experimental protocols. While specific structural details are often proprietary, compounds of this class typically feature a well-defined molecular weight, often ranging from 300 to 600 Daltons, which influences their pharmacokinetic profile, including absorption and distribution within biological systems. Key properties such as melting point, solubility in various solvents (aqueous, organic, and lipid-based), and pH stability are critical determinants for experimental design, particularly when considering in vitro cell culture applications or in vivo administration routes.
The structural characterization of SLU-PP-332 involves a suite of advanced analytical techniques designed to confirm its molecular identity, purity, and stereochemical configuration. Nuclear Magnetic Resonance (NMR) spectroscopy, including 1H NMR and 13C NMR, provides detailed information about the atomic connectivity and local chemical environment, unequivocally confirming the compound’s structure. High-resolution mass spectrometry (HRMS) offers precise molecular weight determination and elucidates fragmentation patterns that are diagnostic of specific substructures, further validating the compound’s identity and detecting potential impurities. Infrared (IR) spectroscopy can identify key functional groups present in the molecule, offering complementary structural insights.
Beyond basic identity, more intricate structural aspects such as chirality, if present, are also meticulously assessed. Chiral chromatography techniques are employed to determine enantiomeric excess or purity, as different enantiomers can exhibit distinct biological activities or metabolic fates in research models. Furthermore, crystalline form analysis using X-ray Diffraction (XRD) can reveal the solid-state structure, which impacts properties such as dissolution rate, stability, and polymorphic purity. These comprehensive structural characterization efforts ensure that researchers are working with a precisely defined chemical entity, minimizing variability in experimental outcomes attributed to inconsistent material quality. The rigorous assessment of these properties underpins the reliability and reproducibility of research involving SLU-PP-332.
Advanced Analytical Methodologies for SLU-PP-332 Purity Assessment
The integrity and reliability of research outcomes derived from studies utilizing SLU-PP-332 are directly contingent upon the purity of the compound. Royal Peptide Labs employs a battery of advanced analytical methodologies to ensure the highest standards of purity, which is critical for minimizing confounding variables in complex biological experiments. High-Performance Liquid Chromatography (HPLC) is a cornerstone of this assessment, providing quantitative determination of the main component and detection of related impurities. Various HPLC modes, including reverse-phase, normal-phase, and ion-exchange chromatography, are selected based on the specific chemical characteristics of SLU-PP-332 and its potential degradants or synthetic byproducts. UV-Vis detection is commonly coupled with HPLC, allowing for sensitive and specific quantification based on the compound’s chromophore properties.
For an even more granular understanding of purity and the identification of unknown impurities, HPLC is often interfaced with mass spectrometry (LC-MS or LC-MS/MS). This hyphenated technique offers unparalleled sensitivity and selectivity, enabling the identification and structural elucidation of impurities present even at trace levels. Gas Chromatography-Mass Spectrometry (GC-MS) is employed for the detection and quantification of residual solvents, which are volatile organic compounds used during the synthesis and purification process. Ensuring residual solvents are below predefined limits is crucial for preventing toxicity or interference in sensitive biological assays. Further analytical checks include Karl Fischer titration for moisture content, as water can impact stability and concentration calculations, and differential scanning calorimetry (DSC) for assessing thermal stability and polymorphic transitions.
The comprehensive purity profile generated through these advanced techniques provides researchers with confidence in the quality of their SLU-PP-332 material. Understanding the impurity landscape allows for more accurate interpretation of experimental results, as any observed biological effects can be confidently attributed to SLU-PP-332 itself, rather than to contaminating substances. Moreover, consistent purity across different batches is essential for comparative studies and long-term research programs. Royal Peptide Labs’ commitment to these rigorous analytical standards is integral to providing high-quality research materials, ensuring that our SLU-PP-332 batches meet the stringent requirements of preclinical investigation.
Key Purity Parameters and Analytical Techniques for SLU-PP-332
| Purity Parameter | Primary Analytical Technique | Purpose and Significance |
|---|---|---|
| Assay Purity (Main Component) | HPLC-UV/PDA, Quantitative NMR (qNMR) | Determines the percentage of the active compound, crucial for accurate dosing and concentration calculations. |
| Related Substances/Impurities | LC-MS/MS, High-Resolution Mass Spectrometry (HRMS) | Identifies and quantifies synthetic byproducts, degradation products, and other structural analogs. |
| Residual Solvents | Gas Chromatography-Mass Spectrometry (GC-MS) | Measures levels of volatile organic solvents remaining from the manufacturing process to ensure research safety and prevent assay interference. |
| Water Content | Karl Fischer Titration | Quantifies moisture levels, which can affect compound stability, potency, and formulation integrity. |
| Non-Volatile Residue (NVR) | Gravimetric Analysis | Detects inorganic salts or other non-volatile contaminants. |
| Chiral Purity (if applicable) | Chiral HPLC/SFC | Separates enantiomers to ensure stereoisomeric integrity, as different stereoisomers can have distinct biological activities. |
Mechanism of Action: SLU-PP-332 as an Estrogen-Related Receptor Agonist
SLU-PP-332 functions as a potent agonist of Estrogen-Related Receptors (ERRs), a family of orphan nuclear receptors comprising three isoforms: ERRα, ERRβ, and ERRγ. Despite their structural homology to classical estrogen receptors (ERs), ERRs do not bind estrogen and primarily regulate distinct transcriptional programs. These receptors are ligand-independent or activated by non-estrogenic endogenous compounds, making the development of selective synthetic agonists like SLU-PP-332 a significant advancement in dissecting their physiological roles. The ERRs are pivotal transcriptional regulators of metabolic pathways, playing crucial roles in mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation. By directly binding to and activating these receptors, SLU-PP-332 orchestrates a cascade of downstream genetic expressions that profoundly influence cellular energy homeostasis and metabolic flexibility.
The agonism of ERRs by SLU-PP-332 leads to the transcriptional upregulation of genes involved in mitochondrial function. Specifically, ERRα is a key regulator of genes encoding mitochondrial proteins, including components of the electron transport chain, TCA cycle enzymes, and fatty acid oxidation enzymes. Activation by SLU-PP-332 is understood to enhance mitochondrial content and function, leading to increased cellular energy expenditure and improved oxidative capacity. This mechanism underpins its potential for investigation in conditions characterized by metabolic dysfunction or where enhanced energy metabolism could offer therapeutic avenues. The precise binding characteristics and selectivity of SLU-PP-332 for specific ERR isoforms are subjects of ongoing investigation, as differential isoform activation could lead to distinct biological outcomes. More detailed information regarding this mechanism can be explored at SLU-PP-332 Mechanism of Action.
Beyond direct mitochondrial regulation, ERR activation by SLU-PP-332 also intersects with broader metabolic networks. For instance, ERRα has been shown to interact with other transcription factors and co-activators, such as PGC-1α (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha), forming a complex transcriptional machinery that coordinates metabolic adaptations. This synergistic action amplifies the impact of SLU-PP-332 on cellular metabolism, influencing glucose uptake, lipid synthesis, and overall energy balance. Research suggests that ERRβ and ERRγ also contribute to metabolic regulation, though their exact roles and the extent of their activation by SLU-PP-332 may vary. The multifactorial nature of ERR signaling highlights SLU-PP-332 as a valuable tool for researchers investigating the intricate interplay between nuclear receptor signaling and metabolic physiology in various preclinical models.
Research Applications: Exercise Mimicry and Metabolic Regulation
SLU-PP-332’s potent agonistic activity on estrogen-related receptors positions it as a highly valuable research compound for investigating complex biological processes, particularly those related to exercise mimicry and metabolic regulation. The concept of “exercise mimicry” refers to the ability of a compound to induce physiological adaptations typically associated with physical activity, such as increased mitochondrial biogenesis, enhanced oxidative capacity, and improved endurance-related parameters, without the need for actual exercise. SLU-PP-332 achieves this by upregulating genes involved in these processes through its ERR agonist activity. Preclinical studies, often involving rodent models, have explored its capacity to improve markers of athletic performance, enhance muscle energetics, and promote a shift towards a more oxidative metabolic phenotype in skeletal muscle and other metabolically active tissues.
In the realm of metabolic research, SLU-PP-332 offers a unique tool for studying glucose and lipid homeostasis. Given the ERR family’s integral role in governing cellular energy metabolism, activation by SLU-PP-332 can significantly modulate pathways involved in glucose utilization, insulin sensitivity, fatty acid oxidation, and thermogenesis. Research applications have included investigations into its effects on systemic glucose control in models of insulin resistance, its potential to alter lipid profiles by promoting the breakdown of triglycerides and fatty acids, and its influence on energy expenditure. These studies aim to dissect the fundamental mechanisms underlying metabolic disorders and explore novel pharmacological strategies to improve metabolic health in preclinical contexts. The numerous PubMed publications and several ClinicalTrials.gov registered studies attest to the significant interest in this area.
Beyond skeletal muscle and systemic metabolism, the research applications of SLU-PP-332 extend to other tissues and organs where ERRs are abundantly expressed and play critical roles. For instance, its effects on cardiac function, liver metabolism, and even neural energy homeostasis are areas of active investigation. Researchers utilize SLU-PP-332 to probe the intricate interplay between ERR signaling and cellular resilience, mitochondrial dysfunction, and the adaptive responses to various physiological stressors. By precisely modulating ERR activity, scientists can gain deeper insights into the pathophysiology of metabolic diseases, age-related decline in metabolic function, and the molecular underpinnings of exercise adaptation, thereby contributing to the fundamental understanding of human physiology and disease progression in preclinical models.
Pharmacokinetic and Pharmacodynamic Considerations in Preclinical Models
Understanding the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of SLU-PP-332 in preclinical models is essential for designing effective research studies and interpreting their outcomes. Pharmacokinetics describes what the body does to the compound, encompassing absorption, distribution, metabolism, and excretion (ADME). Initial PK studies in relevant animal models (e.g., mice, rats) provide crucial data on oral bioavailability, plasma half-life, and tissue distribution. For an ERR agonist like SLU-PP-332, understanding its systemic exposure and its ability to reach target tissues, such as skeletal muscle, liver, and adipose tissue, is paramount. Researchers need to consider the impact of different routes of administration (e.g., oral gavage, subcutaneous injection, intravenous infusion) on absorption rates and overall systemic exposure, as these can dramatically influence the biological effects observed.
Pharmacodynamics, on the other hand, characterizes what SLU-PP-332 does to the body, focusing on the relationship between compound concentration at the site of action and the resulting pharmacological effect. For SLU-PP-332, key PD endpoints include ERR target engagement, transcriptional changes in downstream metabolic genes (e.g., PGC-1α, genes involved in oxidative phosphorylation), and functional metabolic alterations (e.g., enhanced mitochondrial respiration, increased fatty acid oxidation, changes in glucose utilization). Dose-response curves are critical for determining the effective dose range in a specific model, identifying the minimum effective dose, and understanding the saturation of receptor activation. The duration of action and the reversibility of effects are also important PD parameters that inform dosing frequency and experimental timelines.
Careful consideration of PK/PD relationships allows researchers to optimize dosing regimens, extrapolate findings across different preclinical models, and identify potential off-target effects. For instance, if SLU-PP-332 exhibits a short plasma half-life but elicits a sustained cellular response, this suggests persistent target engagement or a prolonged signaling cascade downstream of ERR activation. Conversely, a long half-life without a commensurate prolonged effect might indicate rapid clearance from the target tissue or desensitization of the receptor. Such insights are invaluable for mechanistic studies and for establishing the scientific rationale for future investigations. The iterative process of PK/PD characterization ensures that experimental designs are robust and that observed biological effects are directly attributable to the controlled exposure of SLU-PP-332 within the experimental system.
Methodological Approaches for SLU-PP-332 Application in Research
The effective application of SLU-PP-332 in research requires a meticulous and well-defined methodological approach, tailored to the specific scientific question being addressed. Researchers utilizing SLU-PP-332 must first consider the appropriate experimental model, which can range from various in vitro cell lines and primary cell cultures to complex in vivo animal models. For in vitro studies, precise cell culture techniques, including cell line selection, media composition, and passage number, are critical. Dosage optimization for cell-based assays typically involves establishing a concentration range through preliminary experiments to identify non-toxic yet biologically active concentrations. Endpoints often include gene expression analysis (RT-qPCR, RNA-seq), protein expression (Western blot, immunofluorescence), metabolic flux assays, oxygen consumption rates (OCR), and ATP production.
When transitioning to in vivo animal models, methodological rigor becomes even more paramount. Factors such as animal strain, age, sex, housing conditions, and dietary controls must be carefully standardized to minimize variability. Routes of administration (e.g., oral gavage, intraperitoneal, subcutaneous, intravenous) need to be chosen based on the compound’s physicochemical properties, desired systemic exposure, and the specific research objectives. Dosing frequency and duration of treatment are determined by PK/PD data and the biological endpoint’s kinetics. For instance, studies investigating exercise mimicry might involve chronic administration to induce adaptive metabolic changes, while acute studies could focus on immediate transcriptional responses. Researchers should also establish appropriate control groups, including vehicle controls and positive controls (e.g., known ERR agonists or exercise interventions), to validate experimental findings.
Beyond administration, the selection and execution of analytical techniques for measuring biological outcomes are crucial. Biomarkers reflecting ERR activation and downstream metabolic effects must be chosen carefully. This can include:
- Molecular Endpoints: Analysis of gene expression (e.g., PGC-1α, mitochondrial genes) in target tissues using RT-qPCR or RNA sequencing. Protein levels of mitochondrial components or key metabolic enzymes via Western blotting.
- Biochemical Endpoints: Measurement of substrate utilization (glucose, fatty acids), metabolite levels (lactate, ketone bodies), and enzyme activities (e.g., citrate synthase, cytochrome c oxidase) in tissues or plasma.
- Physiological Endpoints: Assessment of whole-body energy expenditure (indirect calorimetry), glucose tolerance, insulin sensitivity, exercise endurance (treadmill tests), and body composition.
- Histological Endpoints: Staining for mitochondrial content, fiber type switching in muscle, or lipid droplet accumulation in tissues.
Rigorous sample collection protocols, proper tissue processing, and validated assay methodologies are essential to ensure the accuracy and reproducibility of results. Proper storage and handling of SLU-PP-332 are also critical to maintain its integrity throughout the research period.
Ethical Considerations and Responsible Handling of Research Compounds
The utilization of research compounds such as SLU-PP-332 in experimental settings necessitates strict adherence to ethical guidelines and responsible handling protocols. As a compound intended exclusively for research purposes, it is imperative that SLU-PP-332 is never used for human consumption, self-administration, or any non-research application. All experiments involving animals must comply with institutional animal care and use committee (IACUC) regulations and guidelines, ensuring the humane treatment of subjects, minimization of pain and distress, and appropriate experimental design to reduce animal numbers without compromising scientific validity. Research staff must be adequately trained in animal handling, compound administration, and endpoint assessment.
Beyond animal welfare, the safe handling of SLU-PP-332 in the laboratory environment is paramount. Researchers must treat SLU-PP-332 as a potent chemical substance and implement universal laboratory safety precautions. This includes wearing appropriate personal protective equipment (PPE) at all times, such as laboratory coats, safety glasses, and chemical-resistant gloves. Work involving powders or solutions that may aerosolize should be conducted within a certified chemical fume hood or biosafety cabinet to prevent inhalation exposure. Laboratories must have established protocols for spill containment, emergency procedures, and first aid specific to chemical exposures.
Proper storage and disposal of SLU-PP-332 and any associated waste are also critical ethical and safety considerations. Compounds should be stored according to manufacturer recommendations (e.g., refrigerated, protected from light and moisture) to maintain stability and potency, as outlined on the storage and handling guidelines. Expired or unused compounds, as well as waste materials (e.g., used syringes, contaminated glassware, animal carcasses from treated groups), must be disposed of in accordance with institutional, local, state, and federal regulations for chemical and hazardous waste. Maintaining accurate records of compound acquisition, usage, and disposal is not only a matter of regulatory compliance but also an ethical responsibility to ensure accountability and minimize environmental impact. By rigorously upholding these ethical principles and safety protocols, researchers contribute to a culture of scientific integrity and responsible conduct in research.
Interpreting Research Outcomes and Future Directions for SLU-PP-332
Interpreting research outcomes involving SLU-PP-332 requires a critical and nuanced approach, considering both the strengths and limitations of preclinical models and experimental designs. Researchers must carefully evaluate the statistical significance of their findings, ensuring appropriate statistical tests were applied and that sample sizes were sufficient to detect meaningful effects. Beyond statistical significance, the biological relevance of the observed effects is crucial. For example, a statistically significant increase in mitochondrial gene expression might be less impactful if it does not translate into a demonstrable improvement in physiological function, such as enhanced exercise capacity or improved glucose homeostasis in a relevant animal model. Factors such as dose-response, duration of effect, and consistency across multiple experimental replicates or different models further strengthen the interpretability of results.
A significant challenge in interpreting preclinical data is the extrapolation of findings from animal models to human physiology. While animal models offer invaluable insights into mechanisms of action and initial efficacy, species-specific differences in metabolism, ERR expression patterns, and overall physiology can influence the generalizability of results. Researchers must acknowledge these limitations, often designing translational studies that bridge the gap between initial discoveries in rodents and potential applications in more complex biological systems. The “numerous PubMed publications” and “several ClinicalTrials.gov registered studies” involving ERR agonists highlight a growing body of evidence, but each study’s findings must be interpreted within its specific context, considering the model, dosage, and measured endpoints.
Looking ahead, the future directions for SLU-PP-332 research are multifaceted and promising. Continued mechanistic investigations will likely focus on elucidating the isoform-specific roles of ERRα, ERRβ, and ERRγ in various tissues and disease states, potentially leading to the development
Frequently Asked Questions
What is the primary class and mechanism of action for SLU-PP-332?
SLU-PP-332 is classified as an estrogen-related-receptor (ERR) agonist. Its mechanism of action involves activating ERR proteins (ERRα, ERRβ, and ERRγ), which are orphan nuclear receptors belonging to the steroid receptor superfamily. These receptors play crucial roles in regulating various metabolic pathways, including mitochondrial biogenesis, oxidative phosphorylation, glucose homeostasis, lipid metabolism, and thermogenesis, particularly in tissues such as skeletal muscle, heart, liver, and brown adipose tissue. By agonizing these receptors, SLU-PP-332 can modulate gene expression profiles associated with these metabolic processes, making it a valuable tool for investigating exercise-mimetic effects and metabolic regulation in research models.
Why is purity testing critical for SLU-PP-332 in research?
Purity testing is absolutely critical for SLU-PP-332, or any research compound, because impurities can significantly confound experimental results, leading to misinterpretations or irreproducible data. Even minor contaminants can have unforeseen biological activities, interact with the target receptor or other cellular components, or alter the stability and solubility of the primary compound. Rigorous analytical methods, such as High-Performance Liquid Chromatography (HPLC), Liquid Chromatography-Mass Spectrometry (LC-MS), Nuclear Magnetic Resonance (NMR) spectroscopy, and Fourier-Transform Infrared (FTIR) spectroscopy, are employed to confirm the chemical identity, assay purity, and absence of significant impurities. Ensuring high purity directly translates to higher confidence in attributing observed biological effects specifically to SLU-PP-332’s intended mechanism of ERR agonism.
In what types of research studies is SLU-PP-332 most commonly investigated?
SLU-PP-332 is most commonly investigated in research focused on exercise-mimetic effects and metabolic regulation. This includes studies exploring its influence on skeletal muscle mitochondrial function, endurance capacity, energy expenditure, and lipid oxidation. Researchers also utilize SLU-PP-332 to understand its role in modulating glucose homeostasis, insulin sensitivity, and the metabolism of fatty acids in various tissues. Its agonistic action on ERR pathways makes it particularly relevant for investigating strategies for metabolic disorders in preclinical models, allowing scientists to dissect the intricate mechanisms by which exercise benefits metabolism at a molecular level.
What analytical techniques are used to confirm the identity and purity of SLU-PP-332?
To confirm the identity and assess the purity of SLU-PP-332, a suite of advanced analytical techniques is typically employed. Identity confirmation relies heavily on Nuclear Magnetic Resonance (NMR) spectroscopy (e.g., ¹H NMR, ¹³C NMR) to elucidate the molecular structure, alongside High-Resolution Mass Spectrometry (HRMS) to verify the exact molecular weight. Purity is primarily assessed using High-Performance Liquid Chromatography (HPLC) with UV detection, often coupled with Mass Spectrometry (LC-MS) for identifying potential impurities. Fourier-Transform Infrared (FTIR) spectroscopy can provide characteristic functional group information, while Karl Fischer titration quantifies water content, and elemental analysis confirms the empirical formula. These combined methods provide a comprehensive profile of the compound’s quality.
Can SLU-PP-332 be used for human consumption or therapeutic purposes?
Absolutely not. SLU-PP-332 is strictly designated for research-use-only. This means it is intended solely for in vitro (cell culture) and in vivo (animal model) scientific investigations conducted in controlled laboratory settings by qualified researchers. It has not been evaluated for human safety, efficacy, or approved for any therapeutic indication by regulatory bodies. Any discussion of its effects pertains exclusively to observations within preclinical research models, and it must never be considered, administered, or marketed for human consumption, diagnosis, treatment, or prevention of any disease. Adherence to this research-use-only directive is paramount for ethical and scientific integrity.
How should SLU-PP-332 be stored to maintain its stability and purity for research?
Proper storage conditions are crucial for maintaining the stability and purity of SLU-PP-332 for prolonged research utility. Typically, SLU-PP-332, like many research compounds, should be stored in a cool, dark, and dry environment. Specific recommendations often include storage at -20°C or colder, protected from light and moisture, in a tightly sealed container under an inert atmosphere (e.g., nitrogen or argon) to prevent degradation from oxidation or hydrolysis. For solutions, they should generally be prepared fresh and stored at -20°C or -80°C in aliquots to minimize freeze-thaw cycles, which can reduce compound stability over time. Consulting the specific product’s Certificate of Analysis (CoA) for exact storage guidelines is always recommended.
What are the key ethical considerations when conducting research with SLU-PP-332?
When conducting research with SLU-PP-332, researchers must adhere to stringent ethical guidelines, particularly when involving animal models. This includes obtaining approval from an Institutional Animal Care and Use Committee (IACUC) or equivalent regulatory body, ensuring humane treatment of all research animals, minimizing discomfort, and justifying the necessity of animal use. Researchers must also comply with all relevant institutional, national, and international regulations governing the handling, storage, and disposal of research chemicals, including proper personal protective equipment (PPE) usage and waste management protocols. Furthermore, strict adherence to the “research-use-only” designation is an ethical imperative, preventing any misuse or misrepresentation of the compound’s purpose.
How does SLU-PP-332 relate to human estrogen receptors?
While SLU-PP-332 is an “estrogen-related-receptor” (ERR) agonist, it is important to distinguish ERRs from classical estrogen receptors (ERα and ERβ). ERRs are orphan nuclear receptors, meaning their endogenous ligands were initially unknown, though inverse agonists and agonists have since been identified. Despite sharing structural homology with ERs and binding to similar DNA response elements, ERRs typically do not bind endogenous estrogens like estradiol, nor are they directly activated by them. Instead, ERRs play distinct roles in metabolic regulation. SLU-PP-332 specifically targets and activates ERRs, rather than classical estrogen receptors, to exert its effects in metabolic and exercise-mimetic research. This selectivity is crucial for understanding its precise mechanism and avoiding off-target effects associated with classical estrogen receptor modulation.
Scientific References
All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.